Phenotypes associated with this allele

• Allele Symbol: Muc13^tm1.1Mamg
• Allele Name: targeted mutation 1.1 Michael McGuckin
• Allele ID: MGI:6810154
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Muc13^tm1.1Mamg/Muc13^tm1.1Mamg	involves: 129 * C57BL/6	MGI:6818634

Genotype
MGI:6818634

hm1

• Allelic Composition: Muc13^tm1.1Mamg/Muc13^tm1.1Mamg
• Genetic Background: involves: 129 * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

increased susceptibility to colitis induced morbidity/mortality ( J:313870 )

• following DSS-treatment and withdrawal

digestive/alimentary system

rectal hemorrhage ( J:313870 )

• more severe in DSS-treated mice than in similarly treated wild-type mice

increased enterocyte apoptosis ( J:313870 )

• in vivo and in vitro of DSS-exposed colonic intestinal cells

abnormal enterocyte proliferation ( J:313870 )

• reduced in DSS-exposed colonic intestinal cells

abnormal intestinal goblet cell physiology ( J:313870 )

• depletion of goblet cells via thecal size reduction and goblet cell apoptosis 3 days after DSS treatment

diarrhea ( J:313870 )

• more severe in DSS-treated mice than in similarly treated wild-type mice

abnormal crypts of Lieberkuhn morphology ( J:313870 )

• more extensive crypt destruction in DSS-treated mice compared with similarly treated wild-type mice

intestinal ulcer ( J:313870 )

• more in DSS-treated mice compared with similarly treated wild-type mice

large intestinal inflammation ( J:313870 )

• increased neutrophil infiltration with low numbers in the lamina propria in the small and large intestine by 1 year of age

• however, crypt and villus structures are normal

increased susceptibility to induced colitis ( J:313870 )

• before and after treatment, DSS-treated mice exhibit more severe clinical signs of colitis (increased rectal bleeding, diarrhea, body weight loss, lower hematocrit, and disease activity index) and increased macrophage infiltration compared with wild-type mice

• however, DSS-treated mice exhibit normal number of bacteria in direct contact with epithelial cells in the intestine

increased susceptibility to colitis induced morbidity/mortality ( J:313870 )

• following DSS-treatment and withdrawal

small intestinal inflammation ( J:313870 )

• increased neutrophil infiltration with low numbers in the lamina propria in the small and large intestine by 1 year of age

• however, crypt and villus structures are normal

cardiovascular system

rectal hemorrhage ( J:313870 )

• more severe in DSS-treated mice than in similarly treated wild-type mice

endocrine/exocrine glands

abnormal crypts of Lieberkuhn morphology ( J:313870 )

• more extensive crypt destruction in DSS-treated mice compared with similarly treated wild-type mice

growth/size/body

increased susceptibility to weight loss ( J:313870 )

• more severe in DSS-treated mice than in similarly treated wild-type mice

hematopoietic system

decreased hematocrit ( J:313870 )

• in DSS-treated mice

immune system

large intestinal inflammation ( J:313870 )

• increased neutrophil infiltration with low numbers in the lamina propria in the small and large intestine by 1 year of age

• however, crypt and villus structures are normal

increased susceptibility to induced colitis ( J:313870 )

• before and after treatment, DSS-treated mice exhibit more severe clinical signs of colitis (increased rectal bleeding, diarrhea, body weight loss, lower hematocrit, and disease activity index) and increased macrophage infiltration compared with wild-type mice

• however, DSS-treated mice exhibit normal number of bacteria in direct contact with epithelial cells in the intestine

increased susceptibility to colitis induced morbidity/mortality ( J:313870 )

• following DSS-treatment and withdrawal

small intestinal inflammation ( J:313870 )

• increased neutrophil infiltration with low numbers in the lamina propria in the small and large intestine by 1 year of age

• however, crypt and villus structures are normal

cellular

increased enterocyte apoptosis ( J:313870 )

• in vivo and in vitro of DSS-exposed colonic intestinal cells

abnormal enterocyte proliferation ( J:313870 )

• reduced in DSS-exposed colonic intestinal cells

abnormal intestinal goblet cell physiology ( J:313870 )

• depletion of goblet cells via thecal size reduction and goblet cell apoptosis 3 days after DSS treatment